SMAD3 and breast carcinoma: Activated SMAD3 upregulates immune‐related cytokines, leading to enhanced breast cancer stem‐like cell properties, myeloid‐derived suppressor cell (MDSC) recruitment, and triple‐negative breast cancer (TNBC) metastasis.